|
|
|
HEALTHCARE POLICY |
| |
Compliance/Adherence Studies |
 |
| PHP1 |
COMPLIANCE WITH DRUG
TREATMENT IN SWEDEN: AN EPIDEMIOLOGICAL STUDY
Bingefors C, Isacson D, Uppsala University, Uppsala, Sweden |
| PHP2 |
THE
ASSOCIATION OF PRACTICE GUIDELINES AND OTHER FACTORS WITH HOSPITAL
LENGTH OF STAY (LOS) AND MORTALITY IN PATIENTS WITH COMMUNITY-ACQUIRED
PNEUMONIA (CAP), HEART FAILURE (HF) AND SEDATED INTENSIVE CARE
PATIENTS
Bonnet PO1, Chaikledkaew U1, Hopefl A2, Johnson KA1,
1University of Southern California, Los Angeles, CA, USA; 2AmeriNet,
St. Louis, MO, USA |
| PHP3 |
THE
EFFECT OF HOSPITAL COMPLIANCE WITH THE JOINT COMMISSION ON THE
ACCREDITATION OF HEALTHCARE ORGANIZATIONS (JCAHO) PERFORMANCE MEASURES
AND PUBLISHED GUIDELINES ON OUTCOMES OF PATIENTS WITH HEART FAILURE
Chaikledkaew U1, Hopefl A2, Chen SW1, Bonnet PO1, Johnson KA1,
1University of Southern California, Los Angeles, CA, USA; 2AmeriNet,
St. Louis, MO, USA |
| PHP4 |
BIAS
IN CATEGORICAL MEDICATION COMPLIANCE ASSESSMENT
Cramer JA, Yale University School of Medicine, West Haven, CT,
USA |
| PHP5 |
CORRELATIONS BETWEEN A STAGE OF CHANGE MEASURE AND FOUR VALIDATED
MEASURES OF MEDICATION COMPLIANCE
Cook CL, Perri III M, University of Georgia, Athens, GA, USA |
| PHP6 |
THE
INFLUENCE OF SELF-EFFICACY AND COMPLIANCE IN HYPERTENSION PATIENTS,
DIABETES PATIENTS, AND UPPER RESPIRATORY TRACT INFECTIOUS PATIENTS WHO
NEED SHORT COURSE ANTIBIOTICS AT FORT ADISORN HOSPITAL, THAILAND 2000
Auamnoy T, Auamnoy T, Chulalongkorn University, Bangkok,
Thailand |
| PHP7 |
CRITICAL EVALUATION OF INTERVENTIONS TO ENHANCE PATIENT COMPLIANCE
WITH CHRONIC MEDICATIONS
Petrilla AA, Benner JS, ValueMedics Research, LLC,
Alexandria, VA, USA |
| PHP8 |
DIFFERENTIAL ECONOMIC IMPACT OF VARIABLE COMPLIANCE AND VARIABLE
PERSISTENCE WITH PRESCRIBED, LONG-TERM DRUG REGIMENS
Vrijens B1, Tousset E1, Koncz T2, Métry JM2, Urquhart J3,
1AARDEX Ltd, Vise, Belgium; 2AARDEX Ltd, Zug, Switzerland; 3AARDEX
Ltd, Palo Alto, CA, USA |
| |
Consumer Role in Healthcare Studies |
|
|
| PHP9 |
FEASIBILITY OF HEALTH AND WELLNESS PROGRAMS VIA AN EMPLOYER-BASED
INTRANET SITE
Whalen EB1, Thomas P2, Leddy S1, 1Schering-Plough, Kenilworth,
NJ, USA; 2Lockheed Martin, Marietta, GA, USA |
| PHP10 |
IMPACT OF RISK DISCLOSURES IN DIRECT-TO-CONSUMER ADVERTISING ON
ELDERLY CONSUMERS’ BEHAVIORAL INTENT
Nikam PT, Pathak DS, Unnava HR, Dasta JF, The Ohio State
University, Columbus, OH, USA |
| PHP11 |
A
STUDY ON SAVINGS AND HEALTH-RELATED SAVING MOTIVE IN CHINESE RESIDENTS
IN HONG KONG
Zhang JX, Lau E, The Chinese University of Hong Kong, Shatin,
Hong Kong |
| PHP12 |
ATTITUDES AS OUTCOMES: UNDERSTANDING THE COMPLEXITY OF THE HEALTHCARE
CONSUMER
Annunziata K, Bolge SC, Eschmann B, McDonnell DD, Consumer
Health Sciences, Princeton, NJ, USA |
| PHP13 |
IMPROVING THE USE OF MEDICINES AND THE HEALTH KNOWLEDGE OF CONSUMERS
THROUGH CIVIL EDUCATION SYSTEMS
Kao Yang YH1, Chiang SC2, Lin Wu FL3, Chen GT2, Chien SY4, Lin
CS5, Lin HW6, Chen Liu KCS3, 1National Cheng Kung University, Tainan,
Taiwan; 2Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan;
3National Taiwan University, Taipei, Taiwan; 4Changhua Christian
Hospital, Changhua, Taiwan; 5Lotung Poh-Ai Hospital, Ilan, Taiwan;
6Ching-Kang Foundation for Pharmacy Promotion, Taipei, Taiwan |
| |
Drug
Use Policy Studies |
|
|
| PHP14 |
DEALIING WITH
PRESCRIPTION DRUGS: A NURSING HOME DILEMMA
Tennyson DH, Auburn University, Auburn, AL, USA |
| PHP15 |
PUBLIC SUBSIDY OF PHARMACEUTICALS: THE ECONOMIC
CASE FOR AND AGAINST GOVERNMENT INTERVENTION
Davey PJ, Lees M, Medical Technology Assessment Group,
Chatswood West, NSW, Australia |
| PHP16 |
POLISH GUIDELINES FOR COSTING IN
PHARMACOECONOMIC EVALUATION IN COMPARISON TO EXISTING GUIDANCE FOR
COSTING IN OTHER COUNTRIES
Orlewska E1, Mierzejewski P2, Cel M1, 1National Institute of
Public Health, Warsaw, Poland; 2Agency for Registration of Medicinal
Products, Medicinal Devices & Biocides, Warsaw, Poland |
| PHP17 |
SOURCES OF VARIATION IN DRUG COSTS AMONG STATE
MEDICAID PROGRAMS
Brown J, Menzin J, Friedman M, Boston Health Economics, Inc,
Waltham, MA, USA |
| PHP18 |
INCREASED HEALTHCARE UTILIZATION FOR THE ELDERLY
DUE TO INAPPROPRIATE PRESCRIPTION USE
Fu AZ, Liu GG, University of North Carolina at Chapel Hill,
Chapel Hill, NC, USA |
| PHP19 |
PRESCRIPTION DRUG UTILIZATION PATTERNS AND
CHARACTERISTICS OF RETAIL AND MAIL ORDER PHARMACY UTILIZERS
Yokoyama KK, Yu W, WellPoint Pharmacy Management, West Hills,
CA, USA |
| PHP20 |
DOCUMENTING THE RESULTS OF CLINICAL
INTERVENTIONS BY PHARMACISTS IN AN AMBULATORY SETTING
Calvillo JP1, Lake-Wallace SE2, Hayes D1, Rice GK2, Kulkarni AS1,
Sansgiry SS1, 1University of Houston, Houston, TX, USA;
2Kelsey Seybold Clinics, Houston, TX, USA |
| PHP21 |
PHARMACISTS' UTILIZATION AND PERCEPTIONS OF DRUG
INTERACTION PROGRAM WARNINGS
Coffindaffer JW1, Miller K2, Kavookjian J1, Makela E1, 1West
Virginia University School of Pharmacy, Morgantown, WV, USA; 2Johns
Hopkins University Hospital, Baltimore, MD, USA |
| PHP22 |
REVIEWS OF UTAH MEDICAID HIGH UTILIZERS TO
CONTROL DRUG COSTS
Oderda GM1, Gunning K1, LaFleur J1, Stockdale W1, Tyler L1,
Parke D2, Orlando P1, Brixner D1, 1University of Utah, Salt Lake City,
UT, USA; 2Utah Medicaid, Salt Lake City, UT, USA |
| PHP23 |
PRESCRIBING INCENTIVE SCHEMES: DO THEY GIVE
APPROPRIATE INCENTIVES FOR COST-EFFECTIVE PRESCRIBING?
Drummond M1, Mason A1, Hunter J1, Towse A2, Cooke J3,
1University of York, York, UK; 2Office of Health Economics, London,
England; 3South Manchester University Hospitals NHS Trust, Manchester,
UK |
| PHP24 |
GENERIC COMPETITION IN THE PHARMACEUTICAL
INDUSTRY
Saha A1, Grabowski H2, Birnbaum HG3, Bizan O3, Greenberg PE3,
Whitney S1, 1Analysis Group/Economics, New York, NY, USA; 2Duke
University, Durham, NC, USA; 3Analysis Group/Economics, Boston, MA,
USA |
| PHP25 |
DOES THE PAST PREDICT THE FUTURE?
Kleinstiver PW1, Speechley M2, 1Katalyst Health Technology
Assessments, London, ON, Canada; 2University of Western Ontario,
London, ON, Canada |
| PHP26 |
INAPPROPRIATE PRESCRIPTION DRUG USE AND REDUCED
HEALTH STATUS FOR THE ELDERLY
Fu AZ, Liu GG, University of North Carolina at Chapel Hill,
Chapel Hill, NC, USA |
| PHP27 |
HEALTH RELATED QUALITY OF LIFE AMONG
PRESCRIPTION DRUG USERS IN SWEDEN: AN EPIDEMIOLOGICAL SURVEY
Isacson D, Bingefors K, Uppsala University, Uppsala, Sweden
|
| PHP28 |
HEALTH INVOLVEMENT: RELATIONSHIP WITH HEALTH
STATUS AND PATIENT SATISFACTION
Kulkarni AS1, Sansgiry SS1, Hayes D1, Rice GK2,
1University of Houston, Houston, TX, USA; 2Kelsey Seybold Clinics,
Houston, TX, USA |
| PHP29 |
PREDICTIVE FACTORS OF INPATIENT DRUG COSTS IN A
MOTHER-CHILD TEACHING HOSPITAL
Bussieres J1, Lebel D1, Dumont M2, 1Université de Montréal,
Montréal, QC, Canada; 2Sainte-Justine, Montréal, QC, Canada |
| PHP30 |
RATES OF CONTINUATION OF NON FORMULARY
MEDICATIONS FOR CHRONIC DISEASE SUFFERERS IN MULTI-TIERED PHARMACY
BENEFIT PLANS
Nair KV1, Valuck RJ1, Allen RR2, 1University of Colorado Health
Sciences Center, Denver, CO, USA; 2Peak Statistical Services,
Evergreen, CO, USA |
| |
Healthcare Expenditure Studies (Including
Productivity) |
|
|
| PHP31 |
WHAT WE HAVE MISUNDERSTOOD OF THE HIGH RATE OF
OUT-OF-POCKET PAYMENTS IN HEALTHCARE SYSTEMS
Oh E, Imanaka Y, Ishizaki T, Kyoto University, Kyoto, Japan
|
| PHP32 |
A COMPARISON OF HEALTHCARE REIMBURSEMENT
STRATEGIES: HOW ARE CHILDREN WITH CHRONIC CONDITIONS ENROLLED IN STATE
PROGRAMS AFFECTED?
Aydede SK1, Shenkman EA1, Dick A2, Sappington D1, Vogel B1,
1University of Florida, Gainesville, FL, USA; 2University of
Rochester, Rochester, NY, USA |
| PHP33 |
RISK SHARING IN A STATE FUNDED HEALTH SERVICE:
OUTCOMES GUARANTEE PROJECT
Chapman SR, Reeve E, Keele University, Newcastle under Lyme,
Staffordshire, UK |
| PHP34 |
IMPROVING OUTCOMES THROUGH ACCESS TO CRITIQUED
ECONOMIC EVALUATIONS: THE NHS ECONOMIC EVALUATION DATABASE WITHIN THE
HTA REVIEW PROCESS
Nixon J, Duffy SB, Craig D, Armstrong N, Christie J, Glanville
JM, Drummond MF, Kleijnen J, York University, York, UK |
| PHP35 |
AN ANALYSIS OF THE HEALTH AND PRODUCTIVITY COST
BURDEN OF THE PHYSICAL AND MENTAL HEALTH CONDITIONS AFFECTING SIX
LARGE CORPORATIONS IN 1999
Goetzel RZ1, Hawkins K2, Ozminkowski RJ2, Wang S3, 1The MEDSTAT
Group, Inc, Washington, DC, USA; 2The MEDSTAT Group, Inc, Ann Arbor,
MI, USA; 3The MEDSTAT Group, Inc, Cambridge, MA, USA |
| PHP36 |
COSTS ASSOCIATED WITH FALLS IN COMMUNITY
DWELLING ELDERS
Carroll NV1, Slattum PW1, Cox FM2, 1Virginia Commonwealth
University, Richmond, VA, USA; 2Pfizer, Inc, New York, NY, USA |
| PHP37 |
UTILIZATION PATTERNS AND RISK FACTORS FOR HIGH
COST RECIPIENTS IN MEDICAID POPULATION
Guo JJ1, Ludke RL2, Heaton PC1, Moomaw CJ2, Ho M2, Cluxton RJ1,
1University of Cincinnati, Cincinnati, OH, USA; 2University of
Cincinnati IHPHSR, Cincinnati, OH, USA |
| PHP38 |
THREE-YEAR PREDICTIVE MODEL OF MEDICAL COST RISK
AND METHODOLOGICAL ISSUES RELATED TO AN EXPANDED PHARMACY CLAIMS RISK
INDEX
Meyer C, Cooper D, Kalmanowicz J, Vaziri B, AdvancePCS, Hunt
Valley, MD, USA |
| PHP39 |
DOES POOR HEALTH STATUS LEAD TO LOWER INCOME
PRODUCTIVITY?
Liu GG, Sun SX, The University of North Carolina at Chapel
Hill, Chapel Hill, NC, USA |
| PHP40 |
WORK IMPAIRMENT DUE TO CHRONIC DISEASE IN A
POPULATION OF WISCONSIN SCHOOLTEACHERS
Nibbe SS1, Meek PD2, Vermeulen LC3, 1University of Wisconsin
School of Pharmacy and University of Wisconsin Hospital and Clinics'
Center for Drug Policy, Madison, WI, USA; 2University of Wisconsin
School of Pharmacy, Madison, WI, USA; 3University of Wisconsin
Hospital and Clinics, Madison, WI, USA |
| PHP41 |
PHARMACY REIMBURSEMENT FOR PHARMACEUTICAL CARE
SERVICES IN AMBULATORY CARE SETTINGS AT US SCHOOLS OF PHARMACY
Darensbourg J, Daftary M, Dutta A, Howard University, Washington DC,
USA |
| PHP42 |
EVALUATION OF AN INTEGRATED WORKERS’
COMPENSATION/HEALTH INSURANCE PHARMACY BENEFIT PROGRAM: SATISFACTION,
HEALTH OUTCOMES, AND POTENTIAL COST SAVINGS
Saleh SS1, Washington S2, Stapleton D3, Livermore G4,
1SUNY-Albany, Rensselaer, NY, USA; 2New York State Department of Civil
Service, Albany, NY, USA; 3Cornell Center for Policy Research,
Fairfax, VA, USA; 4Cornell Center for Policy Research, Washington, DC,
USA |
| PHP43 |
WITHDRAWN |
| PHP44 |
ROLES OF DIFFERENT TYPES OF HEALTH INSURANCE ON
ACCESS AND UTILIZATION: A COMPARISON BETWEEN DIABETIC AND HYPERTENSIVE
PATIENTS IN THE USA
Huttin CC, ENDEP Research group and IAE Aix en Provence,
Brussels, Belgium |
| PHP45 |
DOES REDUCING LENGTH OF POST-OPERATIVE STAY
REDUCE CANCELLATION OF OPERATIONS?
Donnan PT, Wells M, Harrow A, McKenna E, Thompson A, Davey PG,
University of Dundee, Dundee, Scotland, UK |
| |
Healthcare Management
Studies |
|
|
| PHP46 |
CHARACTERISTICS AND RISK FACTORS FOR HOSPITAL
READMISSION IN MEDICAID POPULATION
Guo JJ1, Ludke RL2, Cluxton RJ1, Moomaw CJ2, Ho M2, Heaton PC1,
Hornung RW2, 1University of Cincinnati, Cincinnati, OH, USA;
2University of Cincinnati IHPHSR, Cincinnati, OH, USA |
| PHP47 |
PHYSICIAN HABIT AS A DETERMINANT OF MEDICATION
CHOICE
Yu AP, Nichol MB, Globe D, University of Southern California,
Los Angeles, CA, USA |
| PHP48 |
HOSPITAL PERFORMANCE EVALUATION METHODS IN A
REGIONAL MANAGED CARE ORGANIZATION: RANDOM-EFFECT OR FIXED-EFFECT
MODEL?
Yu AP1, Chernicoff HO2, Chung RS3, Berthiaume JT3, Darin RM2,
Legorreta AP2, 1University of Southern California & Health Benchmarks
Inc. Fellowship, Los Angeles, CA, USA; 2Health Benchmarks, Inc,
Woodland Hills, CA, USA; 3Hawaii Medical Service Association,
Honolulu, HI, USA |
| PHP49 |
HOSPITALIZATIONS RELATED TO DOMESTIC VIOLENCE:
CHILD ABUSE BY A PARENT OR GUARDIAN
O'Brien JA, Duran PA, Caro J, Caro Research Institute, Concord,
MA, USA |
| PHP50 |
DOMESTIC VIOLENCE: HOSPITALIZATIONS RESULTING
FROM ABUSE BY A SPOUSE OR PARTNER
O'Brien JA, Duran PA, Caro J, Caro Research Institute, Concord,
MA, USA |
| PHP51 |
MEDICAL DEVICE PROBLEMS IN INTENSIVE CARE UNITS:
DETECTION, DANGERS, AND DIVERSITY OF TYPES
Bright RA1, Anderson S2, Frost T2, Wiessner P3, Evans RS2,
Samore MH4, 1Food and Drug Administration, Rockville, MD, USA; 2LDS
Hospital, Salt Lake City, UT, USA; 3University of Utah, Salt Lake
City, UT, USA; 4University of Utah, Salt Lake City, MD, USA |
| PHP52 |
VARIATIONS IN UTILIZATION RATES, CLINICAL
TRIGGERS AND OUTCOMES OF X-RAYS IN A DEVELOPING COUNTRY
Acuin JM1, Valera M2, 1De La Salle University, Dasmarinas,
Cavite, Philippines; 2Philippine Health Insurance Corporation, Manila,
Philippines |
| PHP53 |
MORBIDITY, COMORBIDITY, PHYSICIAN COSTS AND RACE
DIFFERENCES IN MORTALITY AMONG THE MEDICARE ELDERLY
Sherkat DE1, Kilbourne BS2, Husaini BA3, Cain VA3, 1Southern
Illinois University, Carbondale, IL, USA; 2Tennesee State University,
Nashville, TN, USA; 3Tennessee State University, Nashville, TN, USA
|
| PHP54 |
EQUITY OF ACCESS TO HEALTHCARE SERVICES: AN
EVIDENCE-BASED STUDY IN TAIWAN
Liang LY1, Chang HJ2, Huang SM3, Li PC3, Lan CF1, 1National
Yang-Ming University, Taipei, Taiwan; 2Bureau of National Health
Insurance, Taipei, Taiwan; vDepartment of Health, Taipei, Taiwan
|
| PHP55 |
ASSOCIATION BETWEEN INCOME AND HEALTH STATUS IN
THE ELDERLY CHINESE IN HONG KONG
Zhang JX, Ho S, Woo J, The Chinese University of Hong Kong,
Shatin, Hong Kong |
| PHP56 |
DIRECT OBSERVATION IN INTENSIVE CARE UNITS:
MEDICAL DEVICE-RELATED PROBLEMS ASSOCIATED WITH ALARMS
Samore MH1, Anderson S2, Frost T2, Wiessner P1, Evans RS2, Bright
RA3, 1University of Utah, Salt Lake City, UT, USA; 2LDS Hospital,
Salt Lake City, UT, USA; 3Food and Drug Administration, Rockville, MD,
USA |
|
ARTHRITIS/OSTEOPOROSIS |
| |
Clinical
Outcomes/Healthcare Policy Presentations |
|
|
| PAR1 |
USE OF ALTERNATIVE THERAPY, QUALITY OF LIFE, AND
HEALTHCARE SPENDING IN CHINESE PATIENTS WITH OSTEOARTHRITIS
Zhang JX1, Woo J2, Lau E2, 1The Chinese University of Hong
Kong, Shatin, Hong Kong; 2The Chinese University of Hong Kong, Shatin,
NT, Hong Kong |
| PAR2 |
EFFECTS OF A PRIOR AUTHORIZATION POLICY FOR
CYCLOOXYGENASE-2 INHIBITORS ON HEALTH-RELATED OUTCOMES IN A MANAGED
CARE MEDICAID POPULATION
Hartung DM, Touchette DR, Ketchum KL, Haxby DG, Oregon State
University, Portland, OR, USA |
| PAR3 |
IMPACT OF THE INTRODUCTION OF THE COX-2
INHIBITORS ON THE ANALGESIC MARKET IN A PUBLIC EMPLOYEES INDEMNITY
INSURANCE PROGRAM: A FIVE YEAR STUDY
Jenkins TL, Bui TT, Phung QL, Jacobs E, University of Oklahoma,
Oklahoma City, OK, USA |
| PAR4 |
WITHDRAWN |
| PAR5 |
IS A COX-2 INHIBITOR PRIOR AUTHORIZATION WORTH
IT? THE CASE OF KENTUCKY MEDICAID
Wackerbarth SB, Talbert JC, Hattman K, University of
Kentucky, Lexington, KY, USA |
| |
Economic Outcomes
Presentations |
|
|
| PAR6 |
ECONOMIC
ANALYSIS OF NOVEL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) FOR
RHEUMATOID ARTHRITIS (RA) PATIENTS IN A MANAGED CARE SETTING
D'Souza AO1, Crivera C2, Doyle JJ3, 1West Virginia University/
Aventis, Morgantown, WV, USA; 2Rutgers University/Aventis
Pharmaceuticals, Piscataway, NJ, USA; 3Aventis Pharmaceuticals,
Bridgewater, NJ, USA |
| PAR7 |
ASSESSMENT OF THE BURDEN OF RHEUMATOID ARTHRITIS
IN FRENCH HOSPITALS: ANALYSIS OF THE PMSI DATABASE
Baron-Papillon F1, Ryan J2, Grumel O3, Sengupta N4, 1Mapi
Values, Lyon, France; 2Mapi Values, Macclesfield, UK; 3Abbott France,
Rungis Cedex, France; 4Abbott Laboratories, Abbott Park, IL, USA
|
| PAR8 |
COST BURDEN OF HIP AND KNEE REPLACEMENTS IN OHIO
AND IN THE UNITED STATES: ESTIMATED FROM THE NATIONAL HOSPITAL
DISCHARGE SURVEY 2000
Kim S1, Koebel S2, Duffy R2, 1Ohio University, Athens, OH, USA;
2Ohio Department of Health, Columbus, OH, USA |
| PAR9 |
THE IMPLICATIONS OF RHEUMATOID ARTHRITIS IN THE
UK
SECONDARY CARE HEALTHCARE SYSTEM
Ryan J1, Piercy J1, Pang F2, Sengupta N3, Hazleman B4, 1Mapi
Values, Macclesfield, UK; 2Abbott UK, Maidenhead, UK; 3Abbott
Laboratories, Abbott Park, IL, USA; 4University of Cambridge School of
Clinical Medicine, Cambridge, UK |
| PAR10 |
A COST ANALYSIS OF CELECOXIB VERSUS DICLOFENAC
PLUS OMEPRAZOLE FOR THE TREATMENT OF ARTHRITIS IN A GROUP OF
HIGH-RISK CHINESE PATIENTS
You JH, Ho J, Lau W, Lee VW, Chan FK, Lee KK, The Chinese
University of Hong Kong, Hong Kong, China |
| PAR11 |
VERIFICATION OF A DECISION ANALYTIC MODEL
ASSUMPTION USING REAL WORLD PRACTICE DATA: IMPLICATIONS FOR THE
COST-EFFECTIVENESS OF COX-2S
Cox ER, Motheral BR, Mager D, Express Scripts, Maryland
Heights, MO, USA |
| PAR12 |
COST-EFFECTIVENESS OF RALOXIFENE FOR THE
PREVENTION OF OSTEOPOROTIC FRACTURES IN AUSTRALIA
Davey PJ1, Lees M1, Graham-Clarke P2, 1Medical Technology
Assessment Group, Chatswood West, NSW, Australia; 2Eli Lilly Australia
Pty Ltd, West Ryde, NSW, Australia |
| PAR13 |
COMPLIANCE WITH DRUG THERAPIES FOR THE TREATMENT
AND PREVENTION OF OSTEOPOROSIS
McCombs JS1, Thiebaud P1, McLaughlin-Miley C2, 1University of
Southern California, Los Angeles, CA, USA; 2Amgen, Thousand Oaks, CA,
USA |
| PAR14 |
RETROSPECTIVE ANALYSIS OF THE IMPACT OF
MEDICATION NONADHERENCE ON CLINICAL OUTCOMES AND COSTS IN PATIENTS
WITH OSTEOPOROSIS RECEIVING ALENDRONATE USING AN INTEGRATED PAYOR
DATABASE
Peterson AM, Marucci C, Philadelphia College of Pharmacy,
Philadelphia, PA, USA |
| |
Quality of Life
Presentations |
|
|
| PAR15 |
INITIAL VALIDATION OF THE WILLINGNESS TO PAY (WTP)
TECHNIQUE FOR MEASURING HEALTHCARE PREFERENCES IN JUVENILE IDIOPATHIC
ARTHRITIS (JIA)
Brunner HI, Barron A, Cincinnati Children's Hospital Medical
Center, Cincinnati, OH, USA |
| PAR16 |
GASTROINTESTINAL (GI) SYMPTOMS AND
HEALTH-RELATED QUALITY OF LIFE (HRQL) IN JUVENILE IDIOPATHIC ARTHRITIS
(JIA)
Brunner HI, Barron A, Cincinnati Children's Hospital Medical
Center, Cincinnati, OH, USA |
| PAR17 |
COMPARING SHORT FORM AND RAND PHYSICAL AND
MENTAL HEALTH SUMMARY SCORES: RESULTS FROM TOTAL HIP ARTHROPLASTY AND
HIGH-RISK PRIMARY-CARE PATIENTS
Feeny DH1, Blanchard C2, Cote I3, 1Institute of Health
Economics, Edmonton, AB, Canada; 2American Cancer Society, Atlanta,
GA, USA; 3Innovus Research Inc, Burlington, ON, Canada |
| PAR18 |
PREVALENCE OF DEPRESSIVE SYMPTOMATOLOGY AND ITS
RELATIONSHIP TO HRQOL IN ARTHRITIS: A WEB-BASED HEALTH STATUS SURVEY
Nayak RA1, Madnani DM2, Ward J3, 1St. John's University,
Jamaica, NY, USA; 2University of Maryland School of Pharmacy,
Baltimore, MD, USA; 3Knowledge Networks Inc, New York, NY, USA |
| PAR19 |
A UTILITY VALUATION STUDY ASSESSING TREATMENT
OUTCOMES IN OSTEOARTHRITIS
Tilden DP1, Schulz M2, Davey P1, Noble I2, 1M-TAG Pty Ltd,
Chatswood, NSW, Australia; 2Merck Sharpe & Dohme (Australia) Ltd,
Granville, NSW, Australia |
|
CANCER |
| |
Clinical
Outcomes/Healthcare Policy Presentations |
|
|
| PCN1 |
SECOND
TREATMENT PATTERNS IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL
FAILURE: DATA FROM CAPSURE
Mehta SS1, Lubeck DP2, Sadetsky N2, Pasta DJ2, Carroll P2, 1TAP
Pharmaceutical Products Inc, Lake Forest, IL, USA; 2University of
California, San Francisco, San Francisco, CA, USA |
| PCN2 |
DARBEPOETIN ALFA 200 MCG EVERY 2 WEEKS (Q2W) AND
EPOETIN ALFA 40,000 UNITS EVERY WEEK (QW) IN CHEMOTHERAPY-INDUCED
ANEMIA PATIENTS RESULT IN SIMILAR INITIAL HEMOGLOBIN OUTCOMES
Patton J1, Wallace JF2, 1Tennessee Oncology Southern Hills,
Nashville, TN, USA; 2Amgen Inc, Thousand Oaks, CA, USA |
| PCN3 |
PERFORMANCE OF THE MC-PEEK-SCORE FOR SURGICAL
OUTCOME
Sitter H1, Menke H2, Celik I1, Torossian A1, Duda D3, Middeke
M1, Nies C1, Lorenz W1, Junginger T4, Bauhofer A1, 1University
Marburg, Marburg, Germany; 2Clinic Ludwigshafen, Ludwigshafen,
Germany; 3Hildegardis Clinic, Mainz, Germany; 4University Mainz,
Mainz, Germany |
| PCN4 |
ESTIMATING LIFE LOST DUE TO CANCER IN THE US – A
COMPARISON OF LONGITUDINAL AND CROSS-SECTIONAL
MEASURES
Gao X1, Botteman MF1, Madoo L1, Wang Q1, Pashos C2, 1Abt
Associates Clinical Trials, Bethesda, MD, USA; 2Abt Associates
Clinical Trials, Cambridge, MA, USA |
| PCN5 |
HEALTHCARE EXPENDITURES ASSOCIATED WITH SEVEN
TUMOR TYPES OF INTEREST (TOI) USING LARGE EMPLOYERS' CLAIMS DATABASE
Kutikova L1, Bowman L1, Chang S2, Long S2, 1Eli Lilly and
Company, Indianapolis, IN, USA; 2The MEDSTAT Group, Washington, DC,
USA |
| PCN6 |
DOSE CONVERSION OF ERYTHROPOIETIC AGENTS IN
CHEMOTHERAPY-INDUCED ANEMIA: A META-ANALYSIS
Rosberg J1, Oster EF1, Wu E1, Fastenau J2, Piech CT2, 1Analysis
Group/Economics, Boston, MA, USA; 2Ortho Biotech Products, LP,
Bridgewater, NJ, USA |
| PCN7 |
WITHDRAWN |
| |
Economic Outcomes
Presentations |
|
|
| PCN8 |
PREVALENCE RATES AND COST OF DEPRESSION AMONG
PROSTATE CANCER PATIENTS
Chang S1, Orsini LS2, Long S2, Crown W2, 1The Medstat Group,
Inc, Washington, DC, USA; 2The Medstat Group, Inc, Cambridge, MA, USA
|
| PCN9 |
PATIENT CHARACTERISTICS IMPACTING LENGTH OF STAY
AND IN-PATIENT CHARGES AMONG US COLORECTAL CANCER PATIENTS
Donato BMK1, Yuan Y2, Hines P2, 1Bristol-Myers Squibb,
Wallingford, CT, USA; 2Bristol-Myers Squibb, Princeton, NJ, USA |
| PCN10 |
FIVE-YEAR, DIRECT, MEDICAL COSTS AMONG VETERANS
ADMINISTRATION PATIENTS WITH CANCER OF THE SIGMOID COLON
Brown M, Raisch DW, Netravali SS, VA Cooperative Studies
Program Clinical Research Pharmacy Coordinating Center, Albuquerque,
NM, USA |
| PCN11 |
ESTIMATING THE BUDGET AND HEALTH IMPACTS OF
LETROZOLE FOR ADVANCED BREAST CANCER
Mauskopf J1, Sung J2, Sendersky V3, Baker T4, 1RTI Health
Solutions, Research Triangle Park, NC, USA; 2Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA; 3Duke University/Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA; 4MEDTAP
International, Bethesda, MD, USA |
| PCN12 |
ECONOMIC BURDEN OF ACTINIC KERATOSIS AND
SQUAMOUS CELL CARCINOMA IN AMBULATORY CARE
Hartzema AG, University of Florida, Gainesville, FL, USA |
| PCN13 |
PHARMACOECONOMICAL ANALYSIS OF UNFRACTIONATED
HEPARIN VERSUS DALTEPARIN IN PATIENTS WITH MALIGNANCIES
Sura M1, Vorobyov P1, Avxentieva M1, Papsheva V1, Shilova A3,
Momot A3, Barkagan Z4, 1Russian Society for Pharmacoeconomics and
Outcomes Research, Moscow, Russia; 3Altay Medical Institute, Barnoul,
Russia; 4Altai Medical University, Barnaul, Russia |
| PCN14 |
MEDICAL TREATMENT FOR CHRONIC MYELOID LEUKAEMIA
(CML): AVERAGE COST EFFECTIVENESS RATIOS OF FIRST AND SECOND LINE
TREATMENT
Groot MT1, Ossenkoppele GJ2, Kramer MHH3, van den Boom G4,
Huijgens PC2, Uyl-de Groot CA1, 1Erasmus University Rotterdam,
Rotterdam, Netherlands; 2VU Medical Centre, Amsterdam, Netherlands;
3Meander Medical Centre, Amersfoort, Netherlands; 4Novartis Pharma B.V,
Arnhem, Netherlands |
| |
Quality of Life
Presentations |
|
|
| PCN15 |
AGREEMENT OF HEALTH UTILITIES INDEX SCORES AMONG
SURVIVORS OF CANCER IN CHILDHOOD, THEIR PARENTS AND THEIR DOCTORS IN
URUGUAY
Horsman JR1, Fluchel M2, Furlong W1, Castillo L3, Barr RD4,
1McMaster University, Hamilton, ON, Canada; 2University of Washington,
Seattle, WA, USA; 3Hospital Pereira Rossell, Montivideo, Uruguay;
4Hamilton Health Sciences, Hamilton, ON, Canada |
| PCN16 |
SPECIFIC CHOICES AND EXPENDITURES FOR HERBAL
MEDICINES BY CANCER PATIENTS
Arbuckle R, Leak JA, Roach P, Palmer JL, Hogervorst SL, The
University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
|
| PCN17 |
A WEIGHTED INDEX FORM OF THE FACT-L FOR USE IN
ECONOMIC EVALUATION
Kind P1, Macran S1, Christie A2, 1University of York, York, UK;
2AstraZeneca UK Ltd, Luton, Bedfordshire, UK |
| PCN18 |
ASSESSMENT OF PATIENT-REPORTED OUTCOMES AMONG
PATIENTS WITH PROSTATE CANCER
Law AW1, Gause D2, Raut M2, Sung J2, Glendenning A2, McKiernan
J3, 1Duke Clinical Research Institute, Durham, NC, USA; 2Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA; 3Columbia
University, New York, NY, USA |
| PCN19 |
QUALITY OF LIFE PROFILE OF MEN AT-RISK FOR
PROSTATE CANCER: THE FIT AND THE WORRIED WELL
Kulkarni SG1, Watkins Bruner D1, Babb J2, Uzzo R2, Konski A2,
Lai JS3, Cella D3, 1Fox Chase Cancer Center, Cheltenham, PA, USA; 2Fox
Chase Cancer Center, Philadelphia, PA, USA; 3Evanston Northwestern
Healthcare, Evanston, IL, USA |
| PCN20 |
FEAR OF CANCER RECURRENCE AFTER TREATMENT FOR
PROSTATE CANCER: DATA FROM CAPSURE
Mehta SS1, Lubeck DP2, Pasta DJ2, Ye J2, Carroll P2, 1TAP
Pharmaceutical Products Inc, Lake Forest, IL, USA; 2University of
California, San Francisco, San Francisco, CA, USA |
| PCN21 |
DIFFERENCES IN HUSBAND/WIFE PREFERENCES AND
UTILITIES FOR PROSTATE CANCER THERAPIES
Bruner DW1, Hanlon A1, Kulkarni S1, Mazzoni S1, Linton S1,
Konski A2, Pollack A2, Greenberg R2, Beck JR2, 1Fox Chase Cancer
Center, Cheltenham, PA, USA; 2Fox Chase Cancer Center, Philadelphia,
PA, USA |
| PCN22 |
DEVELOPING A MEASUREMENT STRATEGY FOR
PATIENT-REPORTED OUTCOMES: FINDINGS FROM THE NCI’S CANCER OUTCOMES
MEASUREMENT WORKING GROUP
Snyder C1, Lipscomb J1, Gotay CC2, 1National Cancer Institute,
Bethesda, MD, USA; 2University of Hawaii, Honolulu, HI, USA |
| PCN23 |
HEALTH-RELATED QUALITY OF LIFE BURDEN OF HEAD
AND NECK CANCER
Lee JM1, Botteman MF1, Stephens JM1, Kornfield T2, Gramegna P3,
Redaelli A3, 1Abt Associates Clinical Trials, Bethesda, MD, USA;
2Centers for Medicare and Medicaid Services, Baltimore, MD, USA;
3Pharmacia Italia, Milan, Italy |
| PCN24 |
DEVELOPMENT OF A PREFERENCE ELICITATION
INSTRUMENT FOR USE IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES
IN A PROSPECTIVE RANDOMIZED CLINICAL TRIAL
Adamus AT, Chang EL, Arbuckle R, King K, The University
of Texas M.D. Anderson Cancer Center, Houston, TX, USA |
|
EYE & SKIN DISEASES/DISORDERS |
| |
Clinical
Outcomes/Healthcare Policy Presentations |
|
|
| PES1 |
FACTORS INFLUENCING A POTENTIALLY INAPPROPRIATE
DERMATOLOGICAL MEDICATION COMBINATION PRESCRIPTION AMONG U.S.
OUTPATIENT PHYSICIANS
Balkrishnan R, Cook JM, Feldman SR, Fleischer Jr AB, Wake
Forest University School of Medicine, Winston-Salem, NC, USA |
| |
Economic Outcomes
Presentations |
|
|
| PES2 |
COST-EFFECTIVENESS OF BIMATOPROST VERSUS
LATANOPROST PLUS ADJUNCTIVE PRODUCTS FOR GLAUCOMA TREATMENT
Walt J1, Spalding JR2, Habib L3, 1Allergan, Irvine, CA, USA;
2University of Southern California, Los Angeles, CA, USA; 3Keck
Graduate Institute, Claremont, CA, USA |
| PES3 |
A MODEL-BASED PHARMACOECONOMIC ANALYSIS OF
BRIMONIDINE TARTATE 0.2% AS AN ADJUNCTIVE THERAPY TO BETA-BLOCKERS IN
THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION IN ADULT PATIENTS IN
NORWAY
Christensen TL1, Poulsen PB1, Holmstrom S2, Maeland K3, Walt
JG4, 1MUUSMANN Research & Consulting, Kolding, Denmark; 2Allergan,
Mougins, France; 3Allergan, Upplands Vasby, Sweden; 4Allergan, Irvine,
CA, USA |
| PES4 |
COST-EFFECTIVENESS OF BIMATOPROST 0.03% VERSUS A
COMBINATION PRODUCT OF TIMOLOL 0.5% AND DORZOLAMIDE 2.0% FOR GLAUCOMA
Doyle JJ1, Casciano JC1, Walt JG2, 1Analytica Group, New York,
NY, USA; 2Allergan, Irvine, CA, USA |
| PES5 |
MODEL-BASED COMPARATIVE PHARMACOECONOMIC
ANALYSES OF BIMATOPROST 0.03% IN THE TREATMENT OF GLAUCOMA OR OCULAR
HYPERTENSION IN ADULT PATIENTS IN AUSTRIA AND FINLAND
Poulsen PB1, Christensen TL1, Holmstrom S2, Buchholz P3, Walt
J4, 1MUUSMANN Research & Consulting, Kolding, Denmark; 2Allergan,
Mougins, France; 3Allergan, Ettlingen, Germany; 4Allergan, Irvine, CA,
USA |
| PES6 |
ECONOMIC EVALUATION OF PHOTODYNAMIC THERAPY WITH
VERTEPORFIN FOR SMALL SUBFOVEAL CNV LESIONS: THE CASE OF AUSTRALIA
Lees M1, Davey PJ1, Price N1, Aldridge G1, Mudge MAC1, Stokes
J2, 1Medical Technology Assessment Group, Chatswood West, NSW,
Australia; 2Novartis Ophthalmics, North Ryde, NSW, Australia |
| PES7 |
COST-EFFECTIVENESS ANALYSIS OF CATARACT CONTROL
IN 14 WORLD REGIONS
Baltussen R, World Health Organisation, Geneva, Switzerland |
| PES8 |
BURDEN OF ILLNESS OF ECZEMA IN CANADA
Barbeau M, Lalonde H, Novartis Pharma Canada Inc, Dorval, QC,
Canada |
| |
Quality of Life
Presentations |
|
|
| PES9 |
A BASELINE ASSESSMENT OF THE VALIDITY OF THE
39-ITEM NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE IN GERMAN
PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
Lustig SP1, Reichel MB2, Cappelleri J1, Clouse B1, Getter CA1,
Chisholm JA1, 1Pfizer Inc, Groton, CT, USA; 2Universitätsaugenklinik,
Leipzig, Germany |
| PES10 |
PATIENT REPORTED OUTCOMES AND ECONOMIC
IMPLICATIONS OF A REFORMULATION TO IMPROVE BRIMONIDINE 0.2%
Walt J, Lee J, Allergan, Irvine, CA, USA |
| PES11 |
DEGENERATION – A CONJOINT ANALYSIS APPROACH
Hill AR1, Aspinall PA1, Dhillon B2, Ambrecht AM2, Nelson P2, Lumsden
C2, Brice R3, Vickers A3, Buchholz P4, 1Heriot Watt University,
Edinburgh, UK; 2Princess Alexandra Eye Pavilion, Edinburgh, UK;
3Adelphi International Research, Adelphi Mill, Cheshire, UK;
4Allergan, Ettlingen, Germany |
| PES12 |
AN APPRAISAL OF VISION-RELATED QUALITY OF LIFE
INSTRUMENTS
Mallya U, Nau D, University of Michigan, Ann Arbor, MI, USA
|
| PES13 |
COMPARING THE QUALITY OF LIFE EFFECTS OF PRIMARY
FOCAL HYPERHIDROSIS TO OTHER DERMATOLOGICAL CONDITIONS AS ASSESSED BY
THE DERMATOLOGY LIFE QUALITY INDEX (DLQI)
Naumann M1, Hamm H1, Spalding JR2, Kowalski J3, Lee J3,
1University of Würzburg, Würzburg, Germany; 2University of Southern
California, Los Angeles, CA, USA; 3Allergan, Irvine, CA, USA |
| PES14 |
IMPACT OF HYDROTHERAPY CARE ON THE QUALITY OF
LIFE OF CHILDREN
Taïeb C1, Nocera T2, Martincic MA2, Verriere F2, Myon E1,
1Pierre Fabre SA, Boulogne Billancourt, France; 2Laboratoires
Dermatologiques Avène, Lavaur, France |
| PES15 |
THE FRENCH VERSION OF THE CARDIFF ACNE
DISABILITY INDEX
Myon E1, Finlay A2, Verriere F3, Nocera T3, Taïeb C1, 1Pierre
Fabre SA, Boulogne Billancourt, France; 2University of Wales, Cardiff,
UK; 3Laboratoires Dermatologiques Avène, Lavaur, France |
| PES16 |
PSORIASIS AND ATOPIC DERMATITIS:
CROSS-DESCRIPTION OF PATIENTS’ QUALITY OF LIFE
Taïeb C1, Verriere F2, Nocera T2, Myon E1, 1Pierre Fabre SA,
Boulogne Billancourt, France; 2Laboratoires Dermatologiques Avène,
Lavaur, France |
| PES17 |
IMPACT OF HYDROTHERAPY CARES ON THE QUALITY OF
LIFE OF PATIENTS’ SUFFERING FROM SKIN DISEASES
Taïeb C1, Nocera T2, Verriere F2, Myon E1, 1Pierre Fabre SA,
Boulogne Billancourt, France; 2Laboratoires Dermatologiques Avène,
Lavaur, France |
| PES18 |
PSORIASIS AND QUALITY OF LIFE: SPANISH RESULTS
Myon E1, Conesa A2, Del Molino J3, Taïeb C1, 1Pierre Fabre SA,
Boulogne Billancourt, France; 2Pierre Fabre Iberica, Barcelone, Spain;
3Accion Psoriasis, Barcelone, Spain |
| PES19 |
DEVELOPMENT AND VALIDATION OF A HEALTH-RELATED
QUALITY OF LIFE INSTRUMENT FOR WOMEN WITH MELASMA
Balkrishnan R1, McMichael AJ1, Feldman SR1, Camacho F1, Chren
MM2, 1Wake Forest University School of Medicine, Winston-Salem, NC,
USA; 2University of California San Francisco, San Francisco, CA, USA
|
|
GASTROINTESTINAL DISEASES/DISORDERS |
| |
Clinical
Outcomes/Healthcare Policy Presentations |
|
|
| PGS1 |
IMPACT OF RISK MODELING INFORMATION ON THE
PRESCRIBING OF COX-2 INHIBITOR AGENTS
Hoffman L1, Pippins J2, Bullano MF3, Barron JJ3, Daniel G3,
Mayzell G1, 1Blue Cross/Blue Shield of Florida, Jacksonville, FL, USA;
2Pfizer Pharmaceuticals Group, New York, NY, USA; 3Health Core,
Newark, DE, USA |
| PGS2 |
ASSESSMENT OF THE UTILITY OF SALSALATE WITHIN A
COX-2 INHIBITOR CLINICAL USAGE PROTOCOL
Boggie DT, Schaefer MG, DeLattre ML, Morreale AP, Plowman BK,
Veterans Affairs San Diego Healthcare System (119), San Diego, CA, USA
|
| PGS3 |
LOW DOSE ESOMEPRAZOLE (20MG) USE IN GENERAL
PRACTICE: A RETROSPECTIVE AUDIT
Hayes AK1, Hinkley K2, Emmas CE2, 1Brighstone Surgery,
Brighstone, Isle of Wight, UK; 2AstraZeneca UK Ltd, Luton,
Bedfordshire, UK |
| PGS4 |
EFFECT OF COMPETITION ON ANTIULCER-GASTRIC-MEDICATION
ACQUISITION COSTS FOR THE MEDICAID PROGRAM
Guo JJ, Pasquale MK, Cluxton RJ, Moomaw CJ, Zimmerman J, Patel
A, Heaton PC, Kelton CML, University of Cincinnati, Cincinnati, OH,
USA |
| PGS5 |
ECONOMIC ASSESSMENT OF DRUGS AND GI
HOSPITALIZATIONS ASSOCIATED WITH APPLYING VA CRITERIA FOR PRESCRIBING
NONSTEROIDAL ANTI-INFLAMMATORY AGENTS
Harris CL1, Raisch DW2, 1VA Cooperative Studies Program,
Albuquerque, NM, USA; 2VA Cooperative Studies Program Clinical
Research Pharmacy Coordinating Center, Albuquerque, NM, USA |
| |
Economic
Outcomes Presentations |
|
|
| PGS6 |
THE COST-EFFECTIVENESS OF ALTERNATIVE STRATEGIES
IN THE MANAGEMENT OF PATIENTS WITH UNINVESTIGATED DYSPEPSIA (UD):
COMPARING THE CANDYS APPROACH TO EMPIRICAL ANTISECRETORY THERAPY AND
PROMPT ENDOSCOPY
Barkun A1, Crott R2, Fallone CA1, Kennedy WA3, Lachaine J3,
Levinton C3, Armstrong D4, Chiba N5, Thomson ABR6, Veldhuyzen Van
Zanten SJO7, Sinclair P8, Chakraborty B9, Escobedo S9, Smyth S9, White
R9, Nevin K9, 1McGill University Health Centre, Montreal, QC, Canada;
2University of Montreal and EORTC, Brussels, Belgium; 3University of
Montreal, Montreal, QC, Canada; 4McMaster University, Hamilton, ON,
Canada; 5McMaster University, Guelph, ON, Canada; 6University of
Alberta, Edmonton, AB, Canada; 7Dalhousie University, Halifax, NS,
Canada; 8CAG National Office, Oakville, ON, Canada; 9AstraZeneca
Canada Inc, Mississauga, ON, Canada |
| PGS7 |
COST-EFFECTIVENESS ANALYSIS OF ENDOSCOPIC
SCLEROTHERAPY VERSUS LIGATION FOR THE PREVENTION OF REBLEEDING IN
CHILDREN WITH OESOPHAGEAL VARICES
Celinska-Cedro D1, Orlewska E2, Socha P1, Socha J1, 1Children's
Memorial Health Institute, Warsaw, Poland; National Institute of
Public Health, Warsaw, Poland |
| PGS8 |
UTILIZATION IMPACT OF PROTON PUMP INHIBITOR ON
TREATMET COSTS FOR GASTROESOPHAGEAL REFLUX DISEASE USING HEALTHCARE
CLAIMS DATA IN TAIWAN
Lin CW, Lee CT, Bureau of National Health Insurance, Kao-Ping
Branch, Kaohsiung, Taiwan |
| PGS9 |
THE COST-EFFECTIVENESS OF HIGH DOSE ORAL VERSUS
INTRAVENOUS PROTON PUMP INHIBITION IN HIGH-RISK PATIENTS WITH BLEEDING
PEPTIC ULCERS HAVING UNDERGONE THERAPEUTIC ENDOSCOPY
Barkun A1, Adam V1, Kennedy WA2, Fallone CA1, Herba K1, Bardou
M1, 1McGill University Health Centre, Montreal, QC, Canada;
2University of Montreal, Montreal, QC, Canada |
| PGS10 |
TREATMENT PATTERNS AND HEALTHCARE COSTS OF
MEBEVERINE-TREATED IBS PATIENTS: A CASE-CONTROL STUDY
Goettsch WG1, van den Boom G2, Breekveldt N1, Smout A3, Herings
RMC1, 1PHARMO Institute, Utrecht, Netherlands; 2Novartis Pharma,
Arnhem, Netherlands; 3University Medical Centre, Utrecht, Netherlands
|
| PGS11 |
INCIDENCE AND COST OF LAPAROSCOPIC
CHOLECYSTECTOMY IN THE US MANAGED CARE POPULATION
Hanna DB, Zhao SZ, Barr CE, Pharmacia Corporation, Peapack, NJ,
USA |
| PGS12 |
COST-MINIMIZATION ANALYSIS OF A
PHARMACIST-DIRECTED, PANTOPRAZOLE INTRAVENOUS TO ORAL DOSAGE FORM
CONVERSION PROGRAM
Taylor MD1, Greenwood K2, Johns T2, Schmidt JC3, Segal R1,
Hatton R2, 1University of Florida, Gainesville, FL, USA; 2Shands at
the University of Florida, Gainesville, FL, USA; 3Shands HealthCare,
Gainesville, FL, USA |
| |
Quality of Life
Presentations |
|
|
| PGS13 |
DIFFERENCES BETWEN ELDERLY AND YOUNGER ADULTS IN
THE EPIDEMIOLOGY AND TREATMENT OF SYMPTOMATIC GERD AND NOCTURNAL GERD
Ricci JA1, Engelhart LM2, Sloan S2, 1IMR, An AdvancePCS
Company, Hunt Valley, MD, USA; 2Janssen Pharmaceutica, Titusville, NJ,
USA |
| PGS14 |
GASTROESOPHAGEAL REFLUX IN INFANTS: IMPACT ON
THE QOL OF PARENTS
Taïeb C, Marionneau N, Myon E, Pierre Fabre SA, Boulogne
Billancourt, France |
|
INFECTION |
| |
Clinical
Outcomes/Healthcare Policy Presentations |
|
|
| PIN1 |
ASSOCIATION BETWEEN SKIN TATTOOS AND HEPATITIS B
OF 1/2000 PRIVATES AT ADISORN FORT HOSPITAL, THAILAND
Auamnoy T, Mekaroonreung S, Auamnoy T, Chulalongkorn
University, Bangkok, Thailand |
| PIN2 |
TELITHROMYCIN (TEL) RESULTS IN FEWER
HOSPITALIZATIONS THAN AMOXICILLIN-CLAVULANATE (AMC) IN THE OUTPATIENT
TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB)
Chang JR1, Stewart J2, Cadilhac M3, Huppertz E4, Nieman RB1,
1Aventis Pharma, Bridgewater, NJ, USA; 2Aventis Pharma Canada,
Montreal, QC, Canada; 3Aventis Pharma France, Paris, France; 4Aventis
Pharma Germany, Bad Soden, Germany |
| PIN3 |
EFFECTIVENESS OF HAART IN REDUCING VIRAL LOAD (VL)
AMONG A LARGE COHORT OF HIV-INFECTED PATIENTS _ A SIGNIFICANT UNMET
NEED
Wu Y1, Yuan Y2, Mukherjee J1, L'Italien G1, 1Bristol-Myers
Squibb, Wallingford, CT, USA; 2Bristol-Myers Squibb, Princeton, NJ,
USA |
| PIN4 |
THE INFLUENCE OF PRESCRIPTION DRUG COVERAGE ON
ANTIBIOTIC UTILIZATION IN ACUTE RESPIRATORY TRACT INFECTIONS: FINDINGS
FROM THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
Alsultan MS, Larrat EP, University of Rhode Island College of
Pharmacy, Kingston, RI, USA |
| PIN5 |
RELATIONSHIP BETWEEN PRESCRIPTION USE AND
ANTIMICROBIAL RESISTANCE IN THE COMMUNITY: AN EXPLORATION
Sahm D1, Master R1, Roberts C2, McLaughlin T3, Hansen J1,
1Focus Technologies, Inc, Herndon, VA, USA; 2NDCHealth, Yardley, PA,
USA; 3NDCHealth, Phoenix, AZ, USA |
| PIN6 |
IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON
ANTIBIOTIC RESISTANCE
Marshall D1, McGeer A2, Green K2, Gough J1, Laframboise M1, Low DE2,
Grootendorst P3, Jaszewski B4, Simonyi S1, 1Innovus Research
Inc, Burlington, ON, Canada; 2Mount Sinai Hospital, Toronto, ON,
Canada; 3University of Toronto, Toronto, ON, Canada; 4Bayer Inc,
Toronto, ON, Canada |
| PIN7 |
IMPACT OF THE GRIER CONSENT DECREE ON ANTIBIOTIC
COSTS FOR TENNCARE’S MANAGED MEDICAID PROGRAM
Bramley TJ1, Regan T1, Sullivan L2, Eaddy M1, 1Applied Health
Outcomes, Tampa, FL, USA; 2State of Tennessee, Nashville, TN, USA |
| PIN8 |
PATTERNS OF ANTIBIOTIC PRESCRIBING IN TREATING
COMMUNITY-ACQUIRED PNEUMONIA OUTPATIENTS
Wu Y1, Cislo P1, Boening A2, Mukherjee J1, L'Italien G1,
1Bristol Myers Squibb Company, Wallingford, CT, USA; 2Bristol Myers
Squibb Company, Plainsboro, NJ, USA |
| PIN9 |
IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON
ANTIBIOTIC USE AND EXPENDITURES
Marshall D1, Grootendorst P2, Jivraj F3, Simonyi S1,
1Innovus Research Inc, Burlington, ON, Canada; 2University of Toronto,
Toronto, ON, Canada; 3Bayer Inc, Toronto, ON, Canada |
| PIN10 |
THE ALLOCATION OF HIV PREVENTION FUNDS
Earnshaw SR, Richter A, Hicks K, Honeycutt A, RTI
International, Research Triangle Park, NC, USA |
| PIN11 |
DYSLIPIDEMIA MANAGEMENT AMONG HIV-INFECTED
PATIENTS TREATED WITH PROTEASE INHIBITORS (PI)
Darkow T1, Ventura EP1, Wu Y2, 1Prescription Solutions, Costa
Mesa, CA, USA; 2Bristol Myers Squibb Company, Wallingford, CT, USA
|
| PIN12 |
IMPLICATIONS OF APPLYING DIFFERENT NATIONAL
GUIDELINES ADDRESSING SURGICAL ANTIBIOTIC PROPHYLAXIS: A CROSS
SECTIONAL STUDY OF 386 PATIENTS UNDERGOING TOTAL HIP REPLACEMENT
SURGERY
Bedouch P1, Labarère J1, Allenet B2, Fourny M1, François P1,
Calop J1, 1Grenoble University Hospital, Grenoble, France; 2Pharmacy
School, Université Joseph Fourier, Grenoble, France |
| PIN13 |
CHANGES IN ANTIRETROVIRAL (ARV) REGIMENS IN
CLINICAL PRACTICE: RESULTS FROM THE STAR (SCHEMAS
THERAPEUTIQUES-ANTIRETROVIRAUX) COHORT
Lilliu H1, Rozenbaum W2, Raffi F3, Bugnon F3, Massip P4,
Foucher F5, Durand I6, Priol G1, Vincensini JP2, Le Pen C1,
1Clp-santé, Paris, France; 2Hopital Tenon, Paris, France; 3CHRU
Nantes, Nantes, France; 4CHU Toulouse Hôpital Purpan, Toulouse,
France; 5GlaxoSmithKline, Marly-Le-Roi, France; 6Laboratory GSK, Marly
Le Roi, France |
| PIN14 |
POLICY EVALUATION FOR INFLUENZA VACCINATION OF
ELDERLY IN JAPAN
Ohkusa Y, Osaka University, Ibaragi, Osaka, Japan |
| PIN15 |
ESTIMATING USAGE OF SELECTED ANTI-INFECTIVE
DRUGS IN U.S. HOSPITALS
Foster DA, Heller ST, Young JK, Solucient, LLC, Ann Arbor, MI,
USA |
| PIN16 |
ASSESSMENT OF ECONOMIC MODELS OF ANTIRETROVIRAL
THERAPIES IN HIV/AIDS
Shah N1, Stephens J2, Lee J2, Pashos C1, Graff J3, Lenderking
W4, Copley-Merriman C5, 1Abt Associates Clinical Trials, Cambridge,
MA, USA; 2Abt Associates Clinical Trials, Bethesda, MD, USA;
3Statprobe On-Site, Ann Arbor, MI, USA; 4Pfizer Inc, Groton, CT, USA;
5Pfizer Inc, Ann Arbor, MI, USA |
| PIN17 |
THE VALUE OF VACCINATING INFANTS AND CHILDREN
WITH PNEUMOCOCCAL CONJUGATE VACCINE
Ford MW, Wang ECY, Wyeth Pharmaceuticals, Markham, ON, Canada
|
| |
Economic Outcomes
Presentations |
|
|
| PIN18 |
INFLUENZA VACCINATION IN A MALAYSIAN COMPANY:
WHAT RETURN ON INVESTMENT FOR THE EMPLOYER?
Samad AH1, Aji Usul MHB1, Zakaria D1, Ismael R2, Tasset A3,
Baron-Papillon F4, Follet A4, Plun-Favreau J3, 1Petronas (Petroliam
Nasional Berhad), Kuala Lumpur, Malaysia; 2Aventis Pasteur SA,
Petaling Jaya Selangor, Malaysia; 3Aventis Pasteur International,
Lyon, France; 4Mapi Values, Lyon, France |
| PIN19 |
ROUTINE CHILDHOOD VACCINATION AGAINST INFLUENZA:
AN ANALYSIS OF CLINICAL AND ECONOMIC BENEFITS
Weycker DA1, Edelsberg JS1, Halloran ME2, Longini IM2, Nizam A2,
Ciuryla V3, Oster G1, 1Policy Analysis Inc. (PAI), Brookline, MA, USA;
2Emory University, Atlanta, GA, USA; 3Wyeth Research, Collegeville,
PA, USA |
| PIN20 |
COST-CONSEQUENCES OF INFLUENZA VACCINATION FOR
SCHOOL-AGED CHILDREN IN JAPAN
Nakajo K, Yanagisawa S, Aino H, Cai L, Inoue H, Kamae I, Kobe
University, Kobe, Japan |
| PIN21 |
COST-EFFECTIVENESS OF SELECTED INTERVENTIONS TO
REDUCE THE BURDEN OF CHILDHOOD PNEUMONIA AND DIARRHEA: A STANDARDISED
ANALYSIS
Tan-Torres Edejer T1, Aikins M1, Black R2, Hayashi C1, 1World
Health Organization, Geneva, Switzerland; 2Johns Hopkins University,
Baltimore, MD, USA |
| PIN22 |
TELITHROMYCIN (TEL) IS AN EFFECTIVE THERAPY FOR
ADULT OUTPATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) AND IS
ASSOCIATED WITH LOWER OVERALL HEALTHCARE COSTS THAN CLARITHROMYCIN (CLA):
A POOLED ANALYSIS OF DATA FROM TWO INDEPENDENT, RANDOMIZED,
DOUBLE-BLIND STUDIES
Davey PG1, Chang JR2, Stewart J3, Asche CV2, Huppertz
E4, Cadilhac M5, Nieman RB2, 1University of Dundee, Dundee, UK;
2Aventis Pharma, Bridgewater, NJ, USA; 3Aventis Pharma Canada,
Montreal, QC, Canada; 4Aventis Pharma Germany, Bad Soden, Germany;
5Aventis Pharma France, Paris, France |
| PIN23 |
ECONOMIC IMPACT OF ANTIBIOTIC RESISTANCE IN THE
TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
Colice G1, Morley M2, Birnbaum H2, Asche C3, 1Washington
Hospital Center, Washington, DC, USA; 2Analysis Group/Economics,
Boston, MA, USA; 3Aventis Pharmaceuticals, Bridgewater, NJ, USA |
| PIN24 |
COST EFFECTIVENESS ANALYSIS OF LINEZOLID VS.
TEICOPLANIN FOR THE TREATMENT OF SERIOUS GRAM-POSITIVE BACTERIAL
INFECTIONS IN A MULTINATIONAL RANDOMIZED TRIAL
Li JZ1, Willke RJ2, Balan DA3, Nathwani D4, López H5,
Rittenhouse BE1, Tavacoli M6, Mozaffari E1, 1Pharmacia Corp,
Kalamazoo, MI, USA; 2Pharmacia Corp, Peapack, NJ, USA; 3Western
Michigan University, Kalamazoo, MI, USA; 4Tayside University Hospital,
Dundee, Scotland, UK; 5Centro de Infectología, Buenos Aires,
Argentina; 6University of St. Andrews, St. Andrews, Scotland, UK
|
| PIN25 |
A COST-EFFECTIVENESS ANALYSIS OF BACTERIAL
ENDOCARDITIS PROPHYLAXIS FOR FEBRILE CHILDREN WITH CARDIAC LESIONS
Caviness AC1, Cantor SB2, Allen CH1, Ward MA1, 1Baylor College
of Medicine, Houston, TX, USA; 2University of Texas MD Anderson Cancer
Center, Houston, TX, USA |
| PIN26 |
LIFETIME GOVERNMENTAL COSTS OF SEVERE SEQUELAE
OF PNEUMOCOCCAL MENINGITIS IN A WELFARE STATE
Milne RJ1, Heaton-Brown KH1, Lennon D2, Nua M2, 1Health
Outcomes Associates Ltd, Auckland, New Zealand; 2University of
Auckland, Auckland, New Zealand |
| PIN27 |
COST-EFFECTIVENESS OF CEFEPIME VERSUS CEFOTAXIME
WHEN ADDED TO METRONIDAZOLE IN COMPLICATED INTRAABDOMINAL INFECTIONS
Salas M1, Caro J1, Molinar F2, 1Caro Research Institute,
Concord, MA, USA; 2Intensive Care Unit, Medical Center “La Raza”,
Mexico City, Mexico |
| PIN28 |
ESTIMATED COST SAVINGS OF DISCONTINUING
SECONDARY PROPHYLAXIS FOR OPPORTUNISTIC INFECTIONS AFTER IMMUNOLOGICAL
RECONSTITUTION WITH HAART
Becker RV, Gams E, Shakur IM, Ovation Research Group, Highland
Park, IL, USA |
| PIN29 |
PHARMACOECONOMIC EVALUATION OF ANTIMICROBIAL
AGENTS IN THE TREATMENT OF SEXUALLY TRANSMITTED DISEASES IN LAGOS
UNIVERSITY TEACHING HOSPITAL
Suleiman IA, Tayo F, College of Medicine, University of Lagos,
Lagos, Nigeria |
| PIN30 |
HOSPITALIZATION EXPENDITURE OF STREPTOCOCCUS
PYOGENES-ASSOCIATED CELLULITIS IN THE UNITED STATES
Liu Z1, Paramore C2, Ciesla G2, Shulman S3, Ciuryla V1, 1Wyeth
Research, Philadelphia, PA, USA; 2MEDTAP International, Bethesda, MD,
USA; 3Northwestern University, Evanston, IL, USA |
| PIN31 |
THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A
(40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VS. INTERFERON ALFA-2B PLUS
RIBAVIRIN FOR CHRONIC HEPATITIS C (CHC)
Sullivan SD1, Green J2, Patel KK2, Craxi A3, Alberti A4,
Giuliani G5, De Carli C5, 1University of Washington, Seattle, WA, USA;
2Hoffmann-La Roche Inc, Nutley, NJ, USA; 3University of Palermo,
Palermo, Italy; 4Universita degli Studi di Padova, Padova, Italy;
5Roche Milan, Monza (MI), Italy |
| PIN32 |
COST-EFFECTIVENESS ANALYSIS OF ANTI-VIRAL
THERAPIES FOR CHRONIC HEPATITIS B IN TAIWAN
Chan KA1, Pwu RF2, 1Harvard School of Public Health, Boston,
MA, USA; 2iSTAT Healthcare Consulting, Taipei, Taiwan |
| PIN33 |
MEDICAL RESOURCE USE AND DIRECT MEDICAL COST OF
CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN BRAZIL
Meza L1, Glancszpigel R2, Brana N2, Cisneros M2, Callegari M2,
Principe M1, Glancszpigel M3, 1Parexel International, Sao
Paulo, Brazil; 2Parexel International, Buenos Aires, Argentina;
3Advisor for Parexel International Argentina, Buenos Aires, Argentina
|
| PIN34 |
DIRECT MEDICAL COSTS ASSOCIATED WITH HEPATITIS B
VIRUS (HBV) INFECTION IN THE UNITED STATES
Lee TA1, Veenstra D2, Iloeje UH3, Sullivan SD2, 1Hines
VA Hospital, Hines, IL, USA; 2University of Washington, Seattle, WA,
USA; 3Bristol-Myers Squibb, Wallingford, CT, USA |
| PIN35 |
ESTIMATING FUTURE HEPATITIS B VIRUS (HBV)
DISEASE BURDEN IN THE UNITED STATES USING A DISEASE SIMULATION MODEL
Veenstra D1, Sullivan SD1, Iloeje U2, 1University of
Washington, Seattle, WA, USA; 2Bristol-Myers Squibb, Wallingford, CT,
USA |
| PIN36 |
COST-SAVINGS OF AN IV TO PO ACYCLOVIR SWITCH IN
A STANDARDIZED HSV PROPHYLAXIS PROTOCOL ON A BMT UNIT
Spalding JR1, Lightwood J2, Yuen CW2, 1University of Southern
California, Los Angeles, CA, USA; 2University of California, San
Francisco, San Francisco, CA, USA |
| PIN37 |
DOES EFFECTIVE POSTHERPETIC NEURALGIA THERAPY
DECREASE THE COST-EFFECTIVENESS OF ANTIVIRALS FOR ZOSTER?
Smith KJ1, Freeman R2, Roberts MS1, 1University of Pittsburgh
School of Medicine, Pittsburgh, PA, USA; 2Harvard University, Boston,
MA, USA |
| PIN38 |
COST-EFFECTIVENESS OF LOPINAVIR/RITONAVIR
COMPARED TO NELFINAVIR AS FIRST-LINE ANTIRETROVIRAL THERAPY IN
TREATMENT-NAÏVE HIV PATIENTS: A MANAGED CARE PERSPECTIVE
Luo MP1, Botteman MF2, Grad O3, Cifaldi MA1, Ashraf T1, 1Abbott
Laboratories, Abbott Park, IL, USA; 2Abt Associates Clinical Trials,
Bethesda, MD, USA |
| PIN39 |
IMPACT OF METABOLIC ABNORMALITIES (HYPERTENSION,
DIABETES MELLITUS, HYPERLIPIDEMIA) ON RESOURCE CONSUMPTION AND
HEALTHCARE COSTS IN HIV-INFECTED PATIENTS
Iloeje U1, Darkow T2, Tuomari A3, Fontes CL2, 1Bristol-Myers
Squibb Company, Wallingford, CT, USA; 2Prescription Solutions, Costa
Mesa, CA, USA; 3Bristol-Myers Squibb Company, Plainsboro, NJ, USA
|
| PIN40 |
THE COST EFFECTIVENESS OF IMPROVED ADHERENCE TO
ANTIRETROVIRAL TREATMENT
Zaric GS1, Bayoumi AM2, Brandeau ML3, Owens DK4, 1University of
Western Ontario, London, ON, Canada; 2St. Michael's Hospital and
University of Toronto, Toronto, ON, Canada; 3Stanford University,
Stanford, CA, USA; 4VA Palo Alto Health Care System and Stanford
University, Palo Alto, CA, USA |
| PIN41 |
PERTUSSIS VACCINATION IN ADOLESCENTS: COSTS AND
CONSEQUENCES OF NEW PROPOSED VACCINATION PROGRAMMES IN CANADA
Iskedjian M1, Walker JH2, De Serres G3, Einarson T4, Hemels M4,
1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada; 2Brock
University, St. Catharines, ON, Canada; 3Direction de Santé Publique
de Quebec, Beauport, QC, Canada; 4University of Toronto, Toronto, ON,
Canada |
| PIN42 |
COST OF VARICELLA IN POLAND
Glogowski CA1, Gierczynski JM1, Splawinski J2, 1GlaxoSmithKline
Pharmaceuticals S.A, Warsaw, Poland; 2Independent Centre for Economic
and Pharmaceutical Research, Warsaw, Poland |
| PIN43 |
THE EFFECT OF HEALTH PERCEPTION IN MODIFYING
TOTAL HEALTHCARE EXPENDITURES WITHIN AN IMMUNIZED ELDERLY UNITED
STATES POPULATION
Patterson ME, University of North Carolina at Chapel Hill,
Chapel Hill, NC, USA |
| PIN44 |
THE COST OF SEVERE SEPSIS AT A TERTIARY CARE
TEACHING INSTITUTION
Meyer KL1, Faris R2, Rowden A3, 1Applied Health Outcomes,
Tampa, FL, USA; 2University of Tennessee, Memphis, TN, USA; 3The Johns
Hopkins Hospital, Baltimore, MD, USA |
| |
Quality of
Life Presentations |
|
|
| PIN45 |
THE COST EFFECTIVENESS OF PI BASED THERAPY WITH
NELFINIVIR (NLF) COMPARED TO RITONAVIR (RTV) FOR PATIENTS WITH
HIV/AIDS
Anis AH1, Sun H1, Woolcott JC1, Vinduska B2, Walmsley S3,
1University of British Columbia, Vancouver, BC, Canada; 2Canadian HIV
Trials Network, Vancouver, BC, Canada; 3Toronto Hospital (General),
Toronto, ON, Canada |
| PIN46 |
HIV/AIDS PATIENTS: EXPERIENCES WITH
HOSPITALIZATION
Wolosin R, Press Ganey Associates, Inc, South Bend, IN, USA
|
| PIN47 |
SIDE EFFECTS AND THEIR BURDEN ON HIV-INFECTED
PATIENTS
Ayyar Krishnan A1, Jordan JC2, Black LK2, 1University of North
Carolina, Chapel Hill, NC, USA; 2GlaxoSmithkline PLC, Research
Triangle Park, NC, USA |
| PIN48 |
ASSESSING PARENTS’ PREFERENCE FOR A UNIQUE
ANTIBIOTIC DOSE IN THE TREATMENT OF ACUTE OTITIS MEDIA IN CHILDREN BY
USING A WILLINGNESS TO PAY METHOD
Gueylard Chenevier D, Quach C, Dorais M, LeLorier J, Centre
Hospitalier de l'Université de Montréal, Campus Hôtel Dieu, Montreal,
QC, Canada |
| PIN49 |
HOW DOES PATIENT REPORT OF SYMPTOM IMPACT RELATE
TO CLINICAL FUNCTIONING IN CHRONIC BRONCHITIS?
Frank L1, Margolis MK1, Barker C1, Duprat-Lomon I2, Amiot N2,
Sagnier PP3, 1MEDTAP International, Bethesda, MD, USA; 2Bayer Pharma,
Puteaux, France; 3Bayer plc, Slough, UK |
| PIN50 |
VALIDATION OF THE HEALTH RELATED PRODUCTIVITY
QUESTIONNAIRE DIARY (HRPQ-D) ON A SAMPLE OF PATIENTS WITH INFECTIOUS
MONONUCLEOSIS: RESULTS FROM AN OBSERVATIONAL STUDY
Kumar RN1, Hass SL2, Li JZ2, 1University of Michigan, Ann
Arbor, MI, USA; 2Pharmacia Corporation, Kalamazoo, MI, USA |
| PIN51 |
ASSESSING DISEASE-SPECIFIC UTILITY IN RECURRENT
GENITAL HERPES (RGH)
Doward LC1, McKenna SP1, Meads DM1, Ratcliffe J2, Langley PC3,
1Galen Research, Manchester, UK; 2Research Triangle Institute,
Manchester, UK; 33M Pharmaceuticals, St Paul, MN, USA |
|
NEUROLOGICAL & PAIN DISEASES/DISORDERS |
| |
Clinical
Outcomes/Healthcare Policy Presentations |
|
|
| PNP1 |
GALANTAMINE REDUCES
CAREGIVER TIME: AN ANALYSIS OF A NATIONAL SAMPLE OF ALZHEIMER'S
PATIENTS LIVING IN THE COMMUNITY
Meletiche D1, Bolge S2, Small GW3, 1Janssen Pharmaceutica,
Titusville, NJ, USA; 2Consumer Health Sciences, Princeton, NJ, USA;
3UCLA Center for Aging, Neuropsychiatric Institute, Los Angeles, CA,
USA |
| PNP2 |
IMPACT OF RIVASTIGMINE ON TIME TO FIRST
ANTIPSYCHOTIC DRUG USE IN PATIENTS WITH ALZHEIMER'S DISEASE
Suh DC1, Arcona S2, Thomas S2, Chang S2, Powers C1, 1Rutgers
University, Piscataway, NJ, USA; 2Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA |
| PNP3 |
USE OF WHO'S ICIDH-2 CLASSIFICATION SYSTEM IN A
FUNCTIONAL ASSESSMENT OF MIGRAINEURS
Chisolm D1, Pathak D1, Weis KA2, 1The Ohio State University,
Columbus, OH, USA; 2Pfizer, Inc, New York, NY, USA |
| PNP4 |
PHYSICIAN PERCEPTIONS ON THE USE OF MEDICATIONS
FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER
Stockl K1, Hughes T2, Jarrar M1, Secnik K2, Perwien A2,
1Prescription Solutions, Costa Mesa, CA, USA; 2Eli Lilly and Company,
Indianapolis, IN, USA |
| PNP5 |
COMPARISON OF USING NDC OR ICD CODES TO SELECT
PAIN PATIENTS USING DATABASE ANALYSES
Hall J1, Grossman P2, Trukhnova Z1, Huang J2, 1Ingenix, Eden
Prairie, MN, USA; 2Purdue Pharma, Stamford, CT, USA |
| PNP6 |
THE USE OF DISEASE-ALTERING NEW DRUGS FOR
MULTIPLE SCLEROSIS TREATMENT
Ozminkowski RJ1, Marder W2, Hawkins K1, Wang S2, Stallings S3,
Finkelstein S3, Sinskey A3, Wierz D4, 1The MEDSTAT Group, Inc, Ann
Arbor, MI, USA; 2The MEDSTAT Group, Cambridge, MA, USA; 3Massachusetts
Institute of Technology, Cambridge, MA, USA; 4Wyeth Pharmaceuticals,
Exton, PA, USA |
| PNP7 |
COMPLIANCE WITH THREE-TIMES DAILY
METHYLPHENIDATE
IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
Hwang P1, Cosby A2, Laberge ME2, 1Janssen-Ortho Inc, Toronto,
ON, Canada; 2Ipsos-Reid Corporation, Montreal, QC, Canada |
| |
Economic Outcomes
Presentations |
|
|
| PNP8 |
A MARKOV MODEL OF TREATMENT OF NEWLY DIAGNOSED
EPILEPSY IN THE UK – AN ASSESSMENT OF COST-EFFECTIVENESS OF TOPIRAMATE
Remak E1, Hutton J2, Price M3, Peeters K4, Adriaenssen I4,
1MEDTAP International, Inc, Budapest, Hungary; 2MEDTAP International,
London, UK; 3Janssen-Cilag, High Wycombe, Bucks, UK; 4Johnson &
Johnson Pharmaceutical Services, Beerse, Belgium |
| PNP9 |
COST-EFFECTIVENESS ANALYSIS OF PRAMIPEXOLE IN
EARLY PARKINSON’S DISEASE
Noyes K, Dick AW, Holloway RG, Parkinson Study Group,
University of Rochester School of Medicine, Rochester, NY, USA |
| PNP10 |
COST-EFFECTIVENESS OF ATOMOXETINE IN THE
TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND
ADOLESCENTS
Iskedjian M1, Maturi B1, Walker J2, Einarson TR3, Khattak S4,
Carter G4, 1PharmIdeas Research and Consulting Inc, Oakville, ON,
Canada; 2Brock University, St. Catharines, ON, Canada; 3University of
Toronto, Toronto, ON, Canada; 4The Kids Clinic, Whitby, ON, Canada
|
| PNP11 |
MEDICAL CARE COSTS FOR TREATING ATTENTION
DEFICIT/HYPERACTIVITY DISORDER – AN EMPIRICAL STUDY BASED ON A LARGE
ADMINISTRATIVE CLAIM DATA
Sun P, Swindle R, Eli Lilly and Company, Indianapolis, IN, USA
|
| PNP12 |
A COST CONSEQUENCE ANALYSIS OF THE MANAGEMENT OF
ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN THE UK
Vanoverbeke N1, Annemans L2, Ingham M3, Price M4, Adriaenssen
I3, 1HEDM, Meise, Belgium; 2University of Ghent, Meise, Belgium;
3Johnson & Johnson Pharmaceutical Services, Beerse, Belgium;
4Janssen-Cilag, High Wycombe, Bucks, UK |
| PNP13 |
CAREGIVER HEALTH BENEFITS AND ASSOCIATED
REDUCTIONS IN HEALTHCARE COSTS AS A CONSEQUENCE OF TREATING PATIENTS
WITH DONEPEZIL
Winblad B1, Wimo A2, Mastey V3, Shah S3, Haglund A4, Zhang R3,
Miceli R3, Chin W5, 1Karolinska Institute, Alzheimer's Disease
Research Center, Stockholm, Sweden; 2Umeå University, Umeå, Sweden;
3Pfizer Pharmaceuticals Group, Pfizer Inc, New York, NY, USA; 4Pfizer
AB, Täby, Sweden; 5Axia Research, Hamilton, ON, Canada |
| PNP14 |
COST OF MULTIPLE SCLEROSIS BY LEVEL OF
DISABILITY
Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Duke
University, Durham, NC, USA |
| PNP15 |
COST-UTILITY ANALYSIS OF THE TREATMENT OF
RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH GLATIRAMER ACETATE OR
INTERFERON BETA IN SPAIN
Rubio-Terrés C1, Medina F2, Aristegui I1, Izquierdo G2,
1Aventis Pharma, S.A, Madrid, Spain; 2Hospital Universitario Virgen
Macarena, Sevilla, Spain |
| PNP16 |
THE COMPARISON OF DIFFERENT METHODS FOR
DETERMINING THE IMPACT OF MIGRAINE PROPHYLAXIS ON COSTS
Barlev A1, Globe D1, Wu E2, Yu W3, Johnson K1, 1University of
Southern California, Los Angeles, CA, USA; 2Analysis Group/Economics,
Boston, MA, USA; 3WellPoint Pharmacy Management, West Hills, CA, USA |
| PNP17 |
THE ECONOMIC BURDEN OF MIGRAINE AND COMORBID
MENTAL CONDITIONS: RESULTS FROM A CASE-CONTROL STUDY
Pesa JA1, Lage MJ2, 1AstraZeneca LP, Wilmington, DE, USA;
2HealthMetrics Outcomes Research, L.L.C, Groton, CT, USA |
| PNP18 |
ECONOMIC COMPARISON OF FIVE TRIPTAN STRATEGIES
FOR MIGRAINE HEADACHES USING MONTE CARLO SIMULATION
Bell CF, Hu X, Markson L, Merck & Co, Inc, West Point, PA, USA
|
| PNP19 |
COST PER SUCCESSFULLY TREATED PATIENT AS MEASURE
OF EFFECTIVENESS IN COMPARING ELETRIPTAN TO SUMATRIPTAN
Weis KA, Pfizer, Inc, New York, NY, USA |
| PNP20 |
COST UTILITY ANALYSIS OF IMMUNOGLOBULINS (IVIG)
VERSUS PLASMA EXCHANGE (PE) FOR THE TREATMENT OF GUILLAIN BARRE
SYNDROME (GBS)
Jivraj F1, Dranitsaris G2, Nicolle M3, 1Bayer Inc, Toronto, ON,
Canada; 2Princess Margaret Hospital, Toronto, ON, Canada; 3London
Health Sciences Centre, London, ON, Canada |
| PNP21 |
UTILIZATION CHARACTERISTICS OF NARCOTIC
ANALGESICS IN WV WORKERS' COMPENSATION CLAIMANTS
Hassan M1, Islam S2, Doyle E2, Ducatman A2, 1West Virginia
University School of Pharmacy, Morgantown, WV, USA; 2West Virginia
University School of Medicine, Morgantown, WV, USA |
| PNP22 |
PREVALENCE AND MEDICAL CARE COSTS OF BACK PAIN:
COMPARISON OF 1996 AND 1999 NATIONAL ESTIMATES
Mychaskiw MA, Thomas III J, Purdue University, West Lafayette,
IN, USA |
| PNP23 |
COST-EFFECTIVENESS OF DRUG THERAPY FOR
POSTHERPETIC NEURALGIA
Smith KJ1, Freeman R2, Roberts MS1, 1University of Pittsburgh
School of Medicine, Pittsburgh, PA, USA; 2Harvard University, Boston,
MA, USA |
| PNP24 |
ESTIMATES AND PATTERNS OF HEALTHCARE
EXPENDITURES AMONG INDIVIDUALS WITH BACK PAIN IN THE US
Luo X1, Pietrobon R1, Sun SX2, Liu G2, Hey L1, 1Duke University
Medical Center, Durham, NC, USA; 2The University of North Carolina at
Chapel Hill, Chapel Hill, NC, USA |
| |
Quality of Life
Presentations |
|
|
| PNP25 |
DONEPEZIL VERSUS
RIVASTIGMINE UTILIZATION PATTERNS IN A RETROSPECTIVE CLAIMS ANALYSIS
Shah S1, Broderick W2, Solis A2, McRae T1, Mastey V1, 1Pfizer
Pharmaceuticals Group, Pfizer Inc, New York, NY, USA; 2Protocare
Sciences Inc, Santa Monica, CA, USA |
| PNP26 |
VALIDATING THE FACTOR STRUCTURE OF THE DISQ-24
USING STRUCTURAL EQUATION MODELING
Ayyar Krishnan A1, Kwong WJ2, 1University of North Carolina,
Chapel Hill, NC, USA; 2GlaxoSmithKline, Research Triangle Park, NC,
USA |
| PNP27 |
ASSESSING BEHAVIORAL FUNCTIONING IN ALZHEIMER’S
DISEASE: BENCHMARKING WITH THE BEHAVE-AD-FW
Treglia M, Clouse B, Cappelleri J, Pfizer Inc, Groton, CT, USA
|
| PNP28 |
STUDY OF THE QUALITY OF LIFE IN PARKINSON’S
DISEASE PATIENTS IN RUSSIA
Gusev E, Guekht A, Belousov Y, Chikina E, Glushkov K, Russian
State Medical University, Moscow, Russia |
| PNP29 |
CLINITRAC: A NOVEL METHOD FOR EVALUATING OUTCOME
IN PARKINSON DISEASE
Bingefors K, Isacson D, Kristiansen IS, Uppsala University,
Uppsala, Sweden |
| PNP30 |
CHANGES IN QUALITY OF LIFE RESULTING FROM
TREATMENT FOR PERSONS WITH ADVANCED PARKINSON’S DISEASE: SUMANIROLE
VERSUS PLACEBO
DuChane J1, Jenkinson C2, 1Pharmacia Corporation, Kalamazoo,
MI, USA; 2Institute of Health Sciences, Headington, Oxford, UK |
| PNP31 |
PARENT PERCEPTIONS OF MEDICATIONS FOR ADHD: A
PILOT STUDY
Secnik K1, Matza LS2, Rentz A3, Sallee FR4, Mannix S2, 1Eli
Lilly and Company, Indianapolis, IN, USA; 2MEDTAP International,
Bethesda, MD, USA; 3MEDTAP International, Sindelfingen, Germany;
4University of Cincinnati, Cincinnati, OH, USA |
| PNP32 |
QUALITY OF LIFE (QOL) IN PATIENTS WITH PARTIAL
EPILEPSY IN MOSCOW
Guekht A, Gusev E, Belousov Y, Milchakova L, Shpak A, Dzugaeva
F, Mitrokhina T, Russian State Medical University, Moscow, Russia
|
| PNP33 |
HOW DOES AN 11-POINT PAIN SCALE RELATE TO
PREFERENCE ESTIMATES IN PATIENTS WITH CHRONIC PAIN AND CAN IT BE USED
TO PREDICT PREFERENCES?
Lee TA1, Raymundo AL2, Kim SS3, Strauss M3, Sullivan SD4,
1Hines VA Hospital, Hines, IL, USA; 2Pharmacia, Corp, Peapack, NJ,
USA; 3Purdue Pharma L.P, Stamford, CT, USA; 4University of Washington,
Seattle, WA, USA |
| PNP34 |
PATIENT PREFERENCE-BASED TREATMENT
RECOMMENDATIONS FOR ENDOMETRIOSIS PAIN: CHOICE OF METHOD MATTERS
Araki SS1, Kuntz KM1, Llewellyn-Thomas H2, Weinstein MC1,
Hornstein MD3, Tosteson ANA2, 1Harvard School of Public Health,
Boston, MA, USA; 2Dartmouth Medical School, Hanover, NH, USA; 3Brigham
and Women's Hospital, Boston, MA, USA |
| PNP35 |
AGE AND GENDER-STRATIFIED DIFFERENCES IN QUALITY
OF LIFE IN ELDERLY CHRONIC PAIN PATIENTS
Oderda L, Stockdale B, Oderda GM, Donaldson G, Ashburn M,
Brixner D, Lipman A, University of Utah, Salt Lake City, UT, USA
|
|
URINARY & KIDNEY DISEASES/DISORDERS |
| |
Clinical
Outcomes/Healthcare Policy Presentations |
|
|
| PRK1 |
COMPARISON OF DIRECT HEALTH-CARE COST, HOSPITAL
UTILIZATION AND MEDICATION PERSISTENCE BETWEEN EXTENDED RELEASE FORMS
(ER) OF TOLTERODINE AND OXYBUTYNIN IN OVERACTIVE BLADDER/URINARY
INCONTINENCE PATIENTS
Yu YF1, Yu AP2, Ahn J1, Nichol MB1, 1University of Southern
California, Los Angeles, CA, USA; 2USC School of Pharmacy, Los
Angeles, CA, USA |
| PRK2 |
FACTORS ASSOCIATED WITH DIALYSIS TREATMENT COSTS
AMONG MEDICARE ENROLEES
Beilfuss CD1, Hirth RA2, 1University of Michigan and Pfizer
Inc, Ann Arbor, MI, USA; 2University of Michigan, Ann Arbor, MI, USA
|
| PRK3 |
US MEDICAL VISITS WITH DIAGNOSES PATHOGNOMONIC
OF OVERACTIVE BLADDER
Kim S1, Boye ME2, Bhattacharyya SK2, Coyne K3, Dhawan R2, 1Ohio
University, Athens, OH, USA; 2Pharmacia Corporation, Peapack, NJ, USA;
3MEDTAP International, Inc, Bethesda, MD, USA |
| |
Economic
Outcomes Presentations |
|
|
| PRK4 |
COST ANALYSIS OF NON-DIALYSIS RENAL
INSUFFICIENCY (NDRI): AN EMPLOYER'S PERSPECTIVE
Boyce SP1, Buteau S2, Cremieux PY1, Mody SH3, Piech CT3,
1Analysis Group/Economics, Boston, MA, USA; 2Analysis Group/Economics,
Montreal, QC, Canada; 3Ortho Biotech Products, LP, Bridgewater, NJ,
USA |
| PRK5 |
ANALYSIS OF COMORBIDITY, HOSPITAL UTILIZATION
AND COST OF OVERACTIVE BLADDER IN A CALIFORNIA MEDICAID PROGRAM – A
CASE-CONTROL STUDY
Yu YF, Yu AP, Ahn J, Nichol MB, University of Southern
California, Los Angeles, CA, USA |
| PRK6 |
A RETROSPECTIVE CLAIMS ANALYSIS OF THE DIRECT
COSTS OF STRESS URINARY INCONTINENCE
Long S1, Kinchen K2, Orsini LS1, Crown W1, Swindle R2,
1The Medstat Group, Inc, Cambridge, MA, USA; 2Eli Lilly and Company,
Indianapolis, IN, USA |
| PRK7 |
COMPARISON OF TACROLIMUS WITH CYCLOSPORIN IN
KIDNEY TRANSPLANTATION: COST-MINIMISATION AND COST-EFFECTIVENESS
ANALYSES
Klein WH1, McKechnie T2, Schindler TM3, 1PharmaExperience,
Neubiberg, Germany; 2The Lewin Group Quintiles Uk Ltd, Bracknell, UK;
3Fujisawa GmbH, Munich, Germany |
| PRK8 |
COSTS AND CLINICAL CONSEQUENCES OF ALFUZOSIN AND
DOXAZOZIN IN BENIGN PROSTATIC HYPERPLASIA IN UKRAINE
Zaliska O, Zchuravchak A, Lviv Medical University, Lviv,
Ukraine |
| PRK9 |
COST-EFFECTIVENESS OF TAMSULOSIN, DOXAZOSIN AND
TERAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Ohsfeldt RL1, Kreder KJ1, Klein R2, Chrischilles EC1,
1University of Iowa, Iowa City, IA, USA; 2Medical Decision Modeling,
Inc, Indianapolis, IN, USA |
| PRK10 |
COST-MINIMISATION ANALYSIS AND ACCEPTANCE OF
SELF-INJECTING SUBCUTANEOUSLY R-HUEPO WITH RECO-PEN® FOR MANAGEMENT OF
ANAEMIA IN A POPULATION OF FRENCH ADULT PATIENTS ON DIALYSIS
Fagnani F1, Emery C2, Saidani N3, Perez-Niddam K3, 1CEMKA,
Bourg la Reine, France; 2CEMKA EVAL, Bourg la Reine, France; 3Roche,
Neuilly sur Seine, France |
| PRK11 |
THE ECONOMICS OF PHOSPHATE BINDERS IN RENAL
DIALYSIS: A TWO-STAGE STRATEGY FOR MANAGING HYPERPHOSPHATEMIA
Cangialose CB1, Yeh YC1, Pelham RW2, Nolan CR3, Qunibi WY3,
1Covance Health Economics and Outcomes Services Inc, |
| PRK12 |
COMPARING SENSITIVITY TO CHANGE
BETWEEN I-QOL AND SF-36 IN A POPULATION WITH URINARY INCONTINENCE
Bushnell DM, Martin M
Health Research Associates, Inc (HRA), Seattle, WA, USA |
| PRK13 |
DEVELOPMENT OF A QUESTIONNAIRE TO
ASSESS QUALITY OF CARE IN DUTCH DIALYSIS CENTERS
Oppe M, Weijnen TJ, de Charro FT
Erasmus University Rotterdam, Rotterdam, Netherlands |
| PRK14 |
PERCEIVED RISK, VALUE AND QUALITY
OF LIFE FOR PATIENTS WITH OVERACTIVE BLADDER: DEVELOPMENT OF A
PERCEIVED VALUE SCALE
Harpe SE1, Szeinbach SL1, Corey R2
1Ohio State University, Columbus, OH, USA; 2Philadelphia
College of Pharmacy, Philadelphia, PA, USA |
| PRK15 |
DISEASE-SPECIFIC PATIENT-REPORTED
OUTCOME MEASURES IN URINARY INCONTINENCE
Patel KK, Neary M, Hakim Z
Hoffmann-La Roche Inc, Nutley, NJ, USA |
| |
|
|
|
